- Home
- GMAB
GMAB
Genmab A/S ADS
as 12-20-2024 4:00pm EST
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
| Founded: | 1999 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 15.0B | IPO Year: | N/A |
| Target Price: | $43.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 10.80 | EPS Growth: | 14.35 |
| 52 Week Low/High: | $19.85 - $32.88 | Next Earning Date: | 02-12-2025 |
| Revenue: | $2,967,926,227 | Revenue Growth: | 17.75% |
| Revenue Growth (this year): | 30.31% | Revenue Growth (next year): | 16.49% |
Latest Genmab A/S ADS News
GMAB Breaking Stock News: Dive into GMAB Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
Business Wire
12 days ago
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
GlobeNewswire
12 days ago
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
MT Newswires
12 days ago
Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial
Simply Wall St.
13 days ago
Exploring None's High Growth Tech Stocks With Strong Potential
Business Wire
13 days ago
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
GlobeNewswire
14 days ago
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
GlobeNewswire
18 days ago
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Compare GMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GMAB Genmab A/S ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.